Sturge-Weber Syndrome: A Review of Pathophysiology, Genetics, Clinical Features, and Current Management Approache
Top Cited Papers
Open Access
- 1 April 2023
- journal article
- review article
- Published by Taylor & Francis in The Application of Clinical Genetics
- Vol. ume 16, 63-81
Abstract
Sturge-Weber syndrome (SWS) is a congenital, sporadic, and rare neurocutaneous disorder, characterized by the presence of a facial port-wine birthmark (PWB), glaucoma, and neurological manifestations including leptomeningeal angiomatosis and seizures. It is caused by a postzygotic, somatic, gain-of-function variant of the GNAQ gene, and more recently, the GNA11 gene in association with distinctive clinical features. Neuroimaging can help identify and stratify patients at risk for significant complications allowing closer follow-up; although no presymptomatic treatment has been demonstrated to be effective to date, these patients could benefit from early treatment and/or supportive interventions. Choroid plexus (CP) thickness measurements in brain magnetic resonance imaging (MRI) have a high sensitivity and specificity for early and incipient changes in SWS. In contrast, the absence of pathologic findings makes it possible to rule out associated neurological involvement and leads to periodical observation, with new imaging studies only in cases of new clinical signs/symptoms. Periodic ophthalmological examination is also recommended every 3 months during the first year and yearly afterwards to monitor for glaucoma and choroidal hemangiomas. Treatment for SWS depends on the extent and areas that are affected. These include laser surgery for PWB, anticonvulsants in the case of brain involvement, with either seizures or abnormal EEG, and medical treatment or surgery for glaucoma. Sirolimus has been used in a limited number of patients and appears to be a safe and potentially effective treatment for cutaneous and extra-cutaneous features, however controlled clinical studies have not been carried out. Better knowledge of GNAQ/GNA11 molecular pathways will help to develop future targeted treatments.Keywords
This publication has 109 references indexed in Scilit:
- Urine vascular biomarkers in Sturge–Weber syndromeVascular Medicine, 2013
- Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation inGNAQNew England Journal of Medicine, 2013
- Sturge-Weber syndrome with pyogenic granulomaContemporary Clinical Dentistry, 2013
- Aspirin Use in Sturge-Weber SyndromeJournal of Child Neurology, 2012
- Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimodJournal of the American Academy of Dermatology, 2012
- Klippel-Trenaunay and Sturge-Weber overlap syndrome with phakomatosis pigmentovascularisJournal of Pediatric Neurosciences, 2010
- Use of quantitative EEG in infants with port-wine birthmark to assess for Sturge–Weber brain involvementClinical Neurophysiology, 2009
- Central Hypothyroidism and Sturge-Weber SyndromePediatric Neurology, 2008
- Vascular malformationsJournal of the American Academy of Dermatology, 2007
- Sturge-Weber Syndrome: Age of Onset of Seizures and Glaucoma and the Prognosis for Affected ChildrenJournal of Child Neurology, 1995